Physician profile
Christine Chen
NPI 1649518127
$8,854.54
in general payments reported to CMS, 2019-2025
29 companies · $653 in 2025
The $653 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,857 · 2022: $2,847 · 2023: $3,266 · 2024: $232 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,052 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,052.15 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,607.91 | 2021-2024 | |
| Leo Pharma INC. | $1,156.67 | 2021-2023 | Adbry |
| Incyte Corporation | $940.19 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $736.41 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $684.44 | 2021-2023 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $615.18 | 2021-2023 | |
| Pfizer INC. | $472.48 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $341.21 | 2022-2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $273.66 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $250.43 | 2021-2023 | Dupixent |
| Dermavant Sciences, INC. | $249.81 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $200.07 | 2023 | Targretin, Siliq |
| Abbott Laboratories | $187.03 | 2025 | Esprit |
| Ucb, INC. | $153.22 | 2021-2022 | |
| Genzyme Corporation | $144.45 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $141.24 | 2023 | |
| Phadia US INC. | $126.36 | 2021-2023 | Immunocap |
| Galderma Laboratories, L.P. | $109.85 | 2023-2025 | Aklief, Twyneo, Dysport |
| Helsinn Therapeutics (U.S.), INC. | $97.44 | 2022-2023 | Valchlor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.13 | 2024-2025 | Lifevest |
| Lilly USA, LLC | $58.23 | 2021 | |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 | |
| Dermira, INC. | $46.19 | 2021 | |
| Epi Health, LLC | $40.00 | 2021 | |
| Amgen INC. | $34.03 | 2023 | Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.07 | 2025 | Xifaxan |
| Intra-Sana Laboratories | $19.96 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Kyowa Kirin, INC. | $17.46 | 2021 | |
| Glaxosmithkline, LLC. | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.